Abstract

In support of vaccine development, we develop, optimize, and validate assays to monitor immunogenicity of candidate vaccines. In addition, we maintain good laboratory practices to assure data consistency and accuracy in support of regulatory filings. In order to have the most relevant assays of immunogenicity, we continually develop, optimize, and validate new assays to monitor vaccine immunogenicity of vaccines, and develop and institute immunogenicity criteria for vaccine lot release by establishing lot release criteria in animal vaccination studies.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIAAI005073-07
Application #
8148440
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
7
Fiscal Year
2010
Total Cost
$1,282,211
Indirect Cost

  Institution

Name
National Institute of Allergy and Infectious Diseases
Department
Type
DUNS #
City
State
Country
Zip Code

  Publications

Xu, Ling; Pegu, Amarendra; Rao, Ercole et al. (2017) Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. Science 358:85-90
Ferrando-Martinez, Sara; De Pablo-Bernal, Rebeca S; De Luna-Romero, Marta et al. (2017) Thymic Function Failure Is Associated With Human Immunodeficiency Virus Disease Progression. Clin Infect Dis 64:1191-1197
Ewer, Katie; Rampling, Tommy; Venkatraman, Navin et al. (2016) A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. N Engl J Med 374:1635-46
Ledgerwood, Julie E; Hu, Zonghui; Costner, Pamela et al. (2015) Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost. Contemp Clin Trials 44:112-118
Williams, Wilton B; Liao, Hua-Xin; Moody, M Anthony et al. (2015) HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. Science 349:aab1253
Kibuuka, Hannah; Berkowitz, Nina M; Millard, Monica et al. (2015) Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial. Lancet 385:1545-54
Crank, Michelle C; Gordon, Ingelise J; Yamshchikov, Galina V et al. (2015) Phase 1 study of pandemic H1 DNA vaccine in healthy adults. PLoS One 10:e0123969
Kanekiyo, Masaru; Bu, Wei; Joyce, M Gordon et al. (2015) Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site. Cell 162:1090-100
Wheatley, Adam K; Whittle, James R R; Lingwood, Daniel et al. (2015) H5N1 Vaccine-Elicited Memory B Cells Are Genetically Constrained by the IGHV Locus in the Recognition of a Neutralizing Epitope in the Hemagglutinin Stem. J Immunol 195:602-10
Prentice, Heather A; Tomaras, Georgia D; Geraghty, Daniel E et al. (2015) HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition. Sci Transl Med 7:296ra112

Showing the most recent 10 out of 71 publications